Arellano AG, Domínguez CLG, Perales MD, Martínez DJL, Aguirre TJ

Language: Spanish
References: 10
Page: 216-220
PDF size: 560.27 Kb.

ABSTRACT

Background: Pneumocystis pneumonia caused by Pneumocystis jirovecii is one of the most devastating fungal diseases in patients with impaired immunity. Effective antiviral therapies have reduced the burden of PJ in patients with AIDS, but increase in the prevalence of this disease among HIV-negative people receiving immunosuppressive treatments currently reported. Case report: Female 68, diabetic, hypertensive controlled, with 15 years of evolution of rheumatoid arthritis, managed with steroids and methotrexate, which has completed multiple hospitalizations in the last four months by lung disease characterized by dyspnea, dry cough and fever, TAC showing cryptogenic interstitial lung disease, with foci of consolidation and pulmonary fibrosis, transbronchial biopsy and PCR positive for Pneumocystis jirovecii. Handled with trimethoprim-sulfamethoxazole and steroid boluses, improving significantly in 11 days of hospitalization. Conclusions: Real-time PCR is a useful tool for the diagnosis of Pneumocystis pneumonia in non-HIV patients. Hence, a positive Pneumocystis real-time PCR should be taken into account even if the patient does not have symptoms, but has a risk factor like cancer, hematological disorder and/or receives an immunosuppressive therapy.

REFERENCES

1. Fillatre P, Decaux O, Jouneau S, Revest M, Gacouin A, Robert-Gangneux F et al. Incidence of Pneumocystis jirovecii pneumonia among groups at risk in HIV-negative patients. Am J Med. 2014; 127: 1242-1251.

2. Redhead SA, Cushion MT, Frenkel JK, Stringer JR. Pneumocystis and Trypanosoma cruzi: nomenclature and typifications. J Eukaryot Microbiol. 2006; 53: 2-11.

3. Thomas CF Jr, Limper AH. Current insights into the biology and pathogenesis of Pneumocystis pneumonia. Nat Rev Microbiol. 2007; 5: 298-303.

4. Maini R, Henderson KL, Sheridan EA, Lamagni T, Nichols G, Delpech V et al. Increasing Pneumocystis pneumonia, England, UK, 2000-2010. Emerg Infect Dis. 2013; 19: 386-392.

5. Amital A, Shitrit D, Adir Y. The lung in rheumatoid arthritis. Presse Med. 2011; 40: 31-39.

6. Nankivell BJ, Firacative C, Kable K, Chen SC, Meyer W. Molecular epidemiology linking multihospital clusters of opportunistic Pneumocystis jirovecii pneumonia. Clin Infect Dis. 2013; 57: 1058-1059.

7. Fujisawa T, Suda T, Matsuda H, Inui N, Inui N, Nakamura Y et al. Real-time PCR is more specific than conventional PCR for induced sputum diagnosis of Pneumocystis pneumonia in immunocompromised patients without HIV infection. Respirology. 2009; 14: 203-209.

8. Kelly CA, Saravanan V, Nisar M, Arthanari S, Woodhead FA, Price-Forbes AN et al. Rheumatoid arthritis-related interstitial lung disease: associations, prognostic factors and physiological and radiological characteristics —a large multicentre UK study—. Rheumatology (Oxford). 2014; 53:1676-1682.

9. Eddens T, Kolls JK. Pathological and protective immunity to Pneumocystis infection. Semin Immunopathol. 2015; 37: 153-162.

10. Martin GI, Carmona EM, Specks U, Limper AH. Pneumocystis pneumonia in patients treated with rituximab. Chest. 2013; 144: 258-262.